GlassScriptPhysician profile
Lora Ballengee
NPI 1316669906
$1,803.02
in general payments reported to CMS, 2019-2025
17 companies · $316 in 2025
The $316 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $158 · 2023: $752 · 2024: $578 · 2025: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,629 · Education: $16.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,628.57 |
| Education | $16.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $428.74 | 2022-2024 | Farxiga, Fasenra, Breztri |
| Amgen INC. | $282.62 | 2022-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $228.62 | 2024-2025 | |
| Novo Nordisk INC | $193.60 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $181.63 | 2022-2024 | Jardiance, Mounjaro, Emgality |
| Exact Sciences Corporation | $97.84 | 2023-2024 | Cologuard Collection Kit |
| Qol Medical, LLC | $93.13 | 2025 | Sucraid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.93 | 2022-2024 | Jardiance |
| Madrigal Pharmaceuticals | $45.31 | 2025 | Rezdiffra |
| Shield Therapeutics INC | $35.61 | 2023 | Accrufer |
| Aimmune Therapeutics, INC. | $24.20 | 2025 | Vowst |
| Biohaven Pharmaceutical Holding Company LTD. | $23.02 | 2022 | |
| Sanofi-Aventis U.S. LLC | $19.00 | 2023 | |
| Janssen Pharmaceuticals, INC | $18.84 | 2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.55 | 2024 | Xifaxan |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $14.51 | 2025 | Clenpiq |
| Organon LLC | $9.87 | 2025 | Renflexis, Hadlima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lora Ballengee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.